Marketing Authorization In The Eu
-
Upload
clarityeye -
Category
Documents
-
view
22 -
download
1
description
Transcript of Marketing Authorization In The Eu
![Page 1: Marketing Authorization In The Eu](https://reader033.fdocuments.net/reader033/viewer/2022061112/5456ad79af795950098b6beb/html5/thumbnails/1.jpg)
Virgilio Vinas, MD, MPH, PhD.
Universitat Autonoma de Barcelona
Pierre-Marie Curie Paris-V
![Page 2: Marketing Authorization In The Eu](https://reader033.fdocuments.net/reader033/viewer/2022061112/5456ad79af795950098b6beb/html5/thumbnails/2.jpg)
I. General principlesII. National marketing authorization in the EU – still ofuse for the applicant?III. The centralized marketing authorization procedure:procedures, timelines, responsibilitiesIV. The mutual recognition procedure (MRP) and thedecentralized procedure (DCP): timelines,responsibilitiesV. Summary
![Page 3: Marketing Authorization In The Eu](https://reader033.fdocuments.net/reader033/viewer/2022061112/5456ad79af795950098b6beb/html5/thumbnails/3.jpg)
Different licensing procedures, but identical requirements on the documentation: Full application: demonstration of quality, safety and
efficacy Generic application: demonstration of quality for the
generic product plus bioequivalence to the reference product (only possible once data protection period has expired!)
![Page 4: Marketing Authorization In The Eu](https://reader033.fdocuments.net/reader033/viewer/2022061112/5456ad79af795950098b6beb/html5/thumbnails/4.jpg)
Well-established use: demonstration of quality for the product plus literature reference establishing recognized efficacy and an acceptable level of safety
![Page 5: Marketing Authorization In The Eu](https://reader033.fdocuments.net/reader033/viewer/2022061112/5456ad79af795950098b6beb/html5/thumbnails/5.jpg)
Structure of theCommon TechnicalDocument (CTD))
![Page 6: Marketing Authorization In The Eu](https://reader033.fdocuments.net/reader033/viewer/2022061112/5456ad79af795950098b6beb/html5/thumbnails/6.jpg)
1.1 Table of contents (TOC)1.2 Application form1.3 Texts1.4 Information about the experts (CV, signature)1.5 Specific requirements for different types ofApplication
Annex: Environmental risk assessment
![Page 7: Marketing Authorization In The Eu](https://reader033.fdocuments.net/reader033/viewer/2022061112/5456ad79af795950098b6beb/html5/thumbnails/7.jpg)
2.1 CTD TOC Modules 2-52.2 Introduction2.3 Quality Overall Summary2.4 Nonclinical Overview2.5 Clinical Overview2.6 Nonclinical Summary2.7 Clinical Summary
![Page 8: Marketing Authorization In The Eu](https://reader033.fdocuments.net/reader033/viewer/2022061112/5456ad79af795950098b6beb/html5/thumbnails/8.jpg)
One page dealing withPharmacological classMode of actionProposed clinical use
![Page 9: Marketing Authorization In The Eu](https://reader033.fdocuments.net/reader033/viewer/2022061112/5456ad79af795950098b6beb/html5/thumbnails/9.jpg)
1. General information2. Manufacture – Flow diagram3. Characterization -Tabulated summary of data, including graphical representation4. Control of drug substance – Tabulated summary of batch analysis data, with
graphical representation
![Page 10: Marketing Authorization In The Eu](https://reader033.fdocuments.net/reader033/viewer/2022061112/5456ad79af795950098b6beb/html5/thumbnails/10.jpg)
5. Reference standards or materials6. Container closure system (CCS)7. Stability – Tabulated summary of study results, graphical
representation
![Page 11: Marketing Authorization In The Eu](https://reader033.fdocuments.net/reader033/viewer/2022061112/5456ad79af795950098b6beb/html5/thumbnails/11.jpg)
1. Description and composition2. Pharmaceutical development – Tabulated summary of composition of formulations, dissolution profiles3. Manufacture - Flow diagram4. Control of excipients5. Control of drug product – Tabulated summary of batch analysis data, graphical representation
![Page 12: Marketing Authorization In The Eu](https://reader033.fdocuments.net/reader033/viewer/2022061112/5456ad79af795950098b6beb/html5/thumbnails/12.jpg)
6. Reference standards or materials7. Container closure system (CCS)8. Stability – Tabulated summary of stability data, graphical
representation
![Page 13: Marketing Authorization In The Eu](https://reader033.fdocuments.net/reader033/viewer/2022061112/5456ad79af795950098b6beb/html5/thumbnails/13.jpg)
1. Facilities and equipment – Biotech: with summary2. Adventitious agents safety evaluation – Measures to control adventitious agents in production – Summary of reduction factors• Novel excipients2.3.R Regional information
![Page 14: Marketing Authorization In The Eu](https://reader033.fdocuments.net/reader033/viewer/2022061112/5456ad79af795950098b6beb/html5/thumbnails/14.jpg)
3.2 S Drug Substance 3.2 S1 General Information 3.2 S2 Manufacture 3.2 S3 Characterization 3.2 S4 Control of Drug Substance 3.2 S5 Reference Standards or Materials 3.2 S6 Container Closure System 3.2 S7 Stability
![Page 15: Marketing Authorization In The Eu](https://reader033.fdocuments.net/reader033/viewer/2022061112/5456ad79af795950098b6beb/html5/thumbnails/15.jpg)
3.2 P Drug Product 3.2 P1 Description and Composition of the Drug Product 3.2 P2 Pharmaceutical Development 3.2 P3 Manufacture 3.2 P4 Control of Excipients 3.2 P5 Control of Drug Product 3.2 P6 Reference Standards or Materials 3.2 P7 Container Closure System 3.2 P8 Stability
![Page 16: Marketing Authorization In The Eu](https://reader033.fdocuments.net/reader033/viewer/2022061112/5456ad79af795950098b6beb/html5/thumbnails/16.jpg)
A Appendices A1 Facilities and Equipment A2 Adventitious Agents Safety Evaluation A3 Novel Excipients
• R Regional Information
• C Key Literature References
![Page 17: Marketing Authorization In The Eu](https://reader033.fdocuments.net/reader033/viewer/2022061112/5456ad79af795950098b6beb/html5/thumbnails/17.jpg)
Process validation scheme for the drug productMedical deviceDemonstrate compliance with TSE-NfG – CEP or – Scientific data – Provide table A (all applications) as well as tables B
or C (if applicable)
![Page 18: Marketing Authorization In The Eu](https://reader033.fdocuments.net/reader033/viewer/2022061112/5456ad79af795950098b6beb/html5/thumbnails/18.jpg)
The National Procedure – one Member State only The Centralized Procedure – all Member Statessimultaneously The Mutual Recognition Procedure – a selected number of Member States > 1 (chosen by the applicant) The Decentralized Procedure – a selected number of
Member States > 1 (chosen by the applicant)
![Page 19: Marketing Authorization In The Eu](https://reader033.fdocuments.net/reader033/viewer/2022061112/5456ad79af795950098b6beb/html5/thumbnails/19.jpg)
Scope: Marketing authorization in one MS ONLY! New active substances (if not mandatory for the centralized
procedure) Known substances alone or in a new combination Line extensions to national authorizations Abridged applications to national authorizations informed consent generic products to nationally authorized originators/innovators bibliographic applicationsTIMELINE: 210 days
![Page 20: Marketing Authorization In The Eu](https://reader033.fdocuments.net/reader033/viewer/2022061112/5456ad79af795950098b6beb/html5/thumbnails/20.jpg)
Efficacy (Clinical Documentation)Deficiency letter to applicant / oral discussion if necessary
Applicant‘s Response Document
Phase 2 = Evaluation of the response document Quality, Toxicology-Pharmacology, Clinic Decision on the applicationN
ati
on
al
Pro
ced
ure
National committee/board
Marketing Authorization Pre-submission meeting for the MRP
‚Scientific Advice‘Pre-submission meeting
![Page 21: Marketing Authorization In The Eu](https://reader033.fdocuments.net/reader033/viewer/2022061112/5456ad79af795950098b6beb/html5/thumbnails/21.jpg)
The Advantages: Economic aspect: fees are affordable even for small firms(procedure supports a wide variety of the regional ”pharmaceuticallandscape”) No need for translation of the dossier National Marketing authorization (MA) is the basis for the MRP procedure Application forms and requirements of the national competentauthority are well known The Disadvantages: Not all national competent authorities meet the timeline of 210
days Regionally limited validity of the MA
![Page 22: Marketing Authorization In The Eu](https://reader033.fdocuments.net/reader033/viewer/2022061112/5456ad79af795950098b6beb/html5/thumbnails/22.jpg)
Medicinal products developed by means ofone of the following biotechnological processes:
Recombinant DNA technology Controlled expression of gene coding for biologically
active proteins Hybridoma and monoclonal antibody methods
![Page 23: Marketing Authorization In The Eu](https://reader033.fdocuments.net/reader033/viewer/2022061112/5456ad79af795950098b6beb/html5/thumbnails/23.jpg)
As of Nov. 2005, in addition mandatory for• New active substances for the indications– Diabetes– Cancer– Acquired immune deficiency syndrome (HIV)– Neurodegenerative disorder (Alzheimer, …) not licensed before coming into force of regulationEC 726/2004• Orphan medicinal products
![Page 24: Marketing Authorization In The Eu](https://reader033.fdocuments.net/reader033/viewer/2022061112/5456ad79af795950098b6beb/html5/thumbnails/24.jpg)
Cont.From 20th May 2008:• Auto-immune diseases and other immune dysfunctions• Viral diseases• Other extensions to be approved by the Council upon
proposal from the EC
![Page 25: Marketing Authorization In The Eu](https://reader033.fdocuments.net/reader033/viewer/2022061112/5456ad79af795950098b6beb/html5/thumbnails/25.jpg)
Biosimilar Medicinal Products(‘Biogenerics’)
… if biotechnological medicinal products
Mandatory for the Centralized Procedure
![Page 26: Marketing Authorization In The Eu](https://reader033.fdocuments.net/reader033/viewer/2022061112/5456ad79af795950098b6beb/html5/thumbnails/26.jpg)
• Products containing a new active substance not authorized before coming into force of the Regulation EC 726/2004
• Products constituting a significant therapeutic, scientific or technical innovation Will be evaluated on a
case by case basis (consultation of two sponsors out of CHMP and,when needed, the relevant working parties)
![Page 27: Marketing Authorization In The Eu](https://reader033.fdocuments.net/reader033/viewer/2022061112/5456ad79af795950098b6beb/html5/thumbnails/27.jpg)
• Generic of a centrally –authorized product
• Products which are in the interest of patients at community level: - Generic of a National/MRP product - Pandemic medicinal products
![Page 28: Marketing Authorization In The Eu](https://reader033.fdocuments.net/reader033/viewer/2022061112/5456ad79af795950098b6beb/html5/thumbnails/28.jpg)
Where to apply for a centralized MA?
EMEA(European Medicines Agency)
Who will grant a centralized MA?
Decision by the European Commission
![Page 29: Marketing Authorization In The Eu](https://reader033.fdocuments.net/reader033/viewer/2022061112/5456ad79af795950098b6beb/html5/thumbnails/29.jpg)
CHMP appoints rapporteur and co-rapporteur (among its own members) according to objective
criteria which will allow the use of the best available Expertise in the EU on the relevant scientific area.
Rapporteur and co-rapporteur (from different MS) select their team of experts according to the criteria mentioned above.
![Page 30: Marketing Authorization In The Eu](https://reader033.fdocuments.net/reader033/viewer/2022061112/5456ad79af795950098b6beb/html5/thumbnails/30.jpg)
Rapporteur and co-rapporteur perform assessment of dossier and draft assessment report.
All other member states to comment on the assessment report, taking into consideration the information in the
dossier, if necessary “peer-review” of work performed by rapporteur and co-rapporteur.
![Page 31: Marketing Authorization In The Eu](https://reader033.fdocuments.net/reader033/viewer/2022061112/5456ad79af795950098b6beb/html5/thumbnails/31.jpg)
-12 bis -6 m -------- Scientific Advice (national/EMEA) -12m -------------------- Submission strategy -------------------- Pre-sub Meeting EMEA-4 bis -6 m---------- Rapporteur/co-Rapporteur-10 d ----------------- Submission and validation
Pre-submission Phase 1 ClockStop
Phase 2 Opinion Decision
PostAuthorization
![Page 32: Marketing Authorization In The Eu](https://reader033.fdocuments.net/reader033/viewer/2022061112/5456ad79af795950098b6beb/html5/thumbnails/32.jpg)
Pre-submission Phase 1ClockStop
Phase 2
OpinionDecision
PostAuthorization
Day 0• -----------------Start of procedureDay 80--------------- -Rapporteur/Co-Rapporteur’s Assessment ReportsDay 100--------------- Comments of CHMP member States / expertsDay 120----------------Adoption of the consolidated List of Questions) (Q, S, E, SPC, Labelling, PIL)
![Page 33: Marketing Authorization In The Eu](https://reader033.fdocuments.net/reader033/viewer/2022061112/5456ad79af795950098b6beb/html5/thumbnails/33.jpg)
Clock Stop Day 120(GCP/GMP Inspection in parallel)
Restart of the Clock Day 121applicant’s responses during 3 month
Prolongation for 3 month is possible
report from GCP/GMP inspection available?
Pre-submission Phase 1 ClockStop
Phase 2
OpinionDecision
PostAuthorization
![Page 34: Marketing Authorization In The Eu](https://reader033.fdocuments.net/reader033/viewer/2022061112/5456ad79af795950098b6beb/html5/thumbnails/34.jpg)
Day 150 Joint Response Rapp/Co-Rapporteur Assessment Report (JointRespAR)Day 180 • List of Outstanding Issues (LoOI) ?
• Oral Explanation (OE) necessary? • Written explanation before OE? ? New Clock stop ? • Preparation of the Adoption (including SPC) • Preparation of EPAR • withdrawal?
Day 210 • Adoption of CHMP’s opinion
• SPC translation and package leafleat by National Authority • Marketing Authorization by Commission
Pre-submission Phase 1ClockStop Phase 2
OpinionDecision
PostAuthorization
![Page 35: Marketing Authorization In The Eu](https://reader033.fdocuments.net/reader033/viewer/2022061112/5456ad79af795950098b6beb/html5/thumbnails/35.jpg)
Two routes to receive a MA
1. Mutual recognition procedure (MRP) where the medicinal product has already received in a MS
a MA at the time of applicationor
2. Decentralized procedure (DCP)where the medicinal product has not received in a MS a MA at the time of application
![Page 36: Marketing Authorization In The Eu](https://reader033.fdocuments.net/reader033/viewer/2022061112/5456ad79af795950098b6beb/html5/thumbnails/36.jpg)
Describes the procedure to get national MAs inMSs of the EEA for the same medicinal product.
Method of work sharing and harmonization between MS
Mandatory procedures
![Page 37: Marketing Authorization In The Eu](https://reader033.fdocuments.net/reader033/viewer/2022061112/5456ad79af795950098b6beb/html5/thumbnails/37.jpg)
New active substances (if not mandatory for the centralized procedure)
Generic medicinal products to national (and centralized) authorized reference medicinal
Products (if not a biotechnological medicinal product)Informed consentWell established use (WEU) (bibliographic applications)
![Page 38: Marketing Authorization In The Eu](https://reader033.fdocuments.net/reader033/viewer/2022061112/5456ad79af795950098b6beb/html5/thumbnails/38.jpg)
Cont.Line extensions to national authorizationsKnown substances in new combinationHomeopathicsTraditional herbal medicinal products
![Page 39: Marketing Authorization In The Eu](https://reader033.fdocuments.net/reader033/viewer/2022061112/5456ad79af795950098b6beb/html5/thumbnails/39.jpg)
Applicant selects reference member state (RMS) and files first (national) applicationRMS assesses the dossier and clarifies open issuesRMS grants marketing authorization and writes assessment reportSelected concerned member states (CMS) evaluate the assessment report, clarify open questions with information provided in the dossier, and are supposed to recognize theRMS marketing authorization – unless there is a serious risk
to public health.
![Page 40: Marketing Authorization In The Eu](https://reader033.fdocuments.net/reader033/viewer/2022061112/5456ad79af795950098b6beb/html5/thumbnails/40.jpg)
National evaluation and50 days licensing process (normally 2 phase procedure)
Application to firstmember state
First Authorizatio
n
210 days
Assessment reportincluding SPC
Mutual Recognition Process
Further National Authorization(s)
Objections
clarification and dialogue / point ofview of applicant (orally or writing)
resolution of issues
50 days
35 days5 days
Applicant requestmutual recognitionof the referenceauthorization
90 days
![Page 41: Marketing Authorization In The Eu](https://reader033.fdocuments.net/reader033/viewer/2022061112/5456ad79af795950098b6beb/html5/thumbnails/41.jpg)
Applicant submits dossier
Validation Concerned Member States
Day 0 - 50 - Evaluation of assessment report and experts reports (and dossier) - Quality (Chemical, Pharmaceutical and Biological Documentation) - Safety ( Toxicological-Pharmacological Documentation) - Efficacy (Clinical Documentation) -Comments/Objections to Reference Member State and Applicant
Applicants Response Document
Evaluation of the response documentDay 75 Break out session /discussion
Day 90 Decision on the application
EU-MSs National authorities/agencies
Marketing authorizationApplicant submits national texts
![Page 42: Marketing Authorization In The Eu](https://reader033.fdocuments.net/reader033/viewer/2022061112/5456ad79af795950098b6beb/html5/thumbnails/42.jpg)
Applicant can choose procedureConsultation between MS´s before the first MA is issued‘Clock stop’ period to clarify open issuesFinal AR, SPC, PL and labelingDecision about the MA at the ‘same time’ in MS´s of the EU/EEATimeline: 210 days, i.e. up to 180 days less thanMRP (90 days for AR + 90 days for MR-phase)
![Page 43: Marketing Authorization In The Eu](https://reader033.fdocuments.net/reader033/viewer/2022061112/5456ad79af795950098b6beb/html5/thumbnails/43.jpg)
Applicant selects RMS and CMS. All authorities receive the application and documentation simultaneouslyRMS assesses the dossier and clarifies open issues, CMS may already commentRMS writes assessment reportApplicant clarifies questions asked by RMS and CMSRMS and CMS grant marketing authorization at the same time, if application is o.k. for themCMS with open issues (risk to public health) can file for arbitration without delaying the marketing authorization in
other member states
![Page 44: Marketing Authorization In The Eu](https://reader033.fdocuments.net/reader033/viewer/2022061112/5456ad79af795950098b6beb/html5/thumbnails/44.jpg)
Validation 14 days
Assessment I RMS assessment, Preliminary AR, comments from CMS, clock-stop Applicant submit valid response document, restart, RMS prepares Draft AR, SPC, PL and Labeling (= Day 120)
Assessment II CMS comments, Break out Session, FAR, approval or CMD-Referral (= Day 210)
National step granting of a national MA (= Day 240)
![Page 45: Marketing Authorization In The Eu](https://reader033.fdocuments.net/reader033/viewer/2022061112/5456ad79af795950098b6beb/html5/thumbnails/45.jpg)
If no agreement between RMS/CMS can be reached at end of procedure
Referred to Coordination Group (CG) - 60 days for negotiation between the MS concerned (RMS and CMSs) - Consultation of the applicant in written or oral form
![Page 46: Marketing Authorization In The Eu](https://reader033.fdocuments.net/reader033/viewer/2022061112/5456ad79af795950098b6beb/html5/thumbnails/46.jpg)
Still disagreement after this consultation – theelements of disagreement are forwarded to theAgency Arbitration, referral to CHMP MS´s that are in agreement with the AR and SPC may authorize the medicinal product, without waiting for the outcome of the procedure
![Page 47: Marketing Authorization In The Eu](https://reader033.fdocuments.net/reader033/viewer/2022061112/5456ad79af795950098b6beb/html5/thumbnails/47.jpg)
Four different licensing procedures available
No difference in requirements regarding quality, safety and efficacy
For certain products, reduced quantity of data regarding safety and efficacy (generics, line extensions)
Target time for approval: 210 days (MRP: plus 90 days)
![Page 48: Marketing Authorization In The Eu](https://reader033.fdocuments.net/reader033/viewer/2022061112/5456ad79af795950098b6beb/html5/thumbnails/48.jpg)
http://www.emea.eu.int/
http://ec.europa.eu/enterprise/index_en.htm
http://ec.europa.eu/enterprise/pharmaceuticals/eu dralex/homev2.htm
http://heads.medagencies.org/
http://www.bfarm.de
![Page 49: Marketing Authorization In The Eu](https://reader033.fdocuments.net/reader033/viewer/2022061112/5456ad79af795950098b6beb/html5/thumbnails/49.jpg)